The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
 
Nitzan Zohar
No Relationships to Disclose
 
Edik Matthew Blais
Employment - AstraZeneca (I); BridgeBio (I); Emerald Cloud Labs (I); HI-Bio (I); Perthera
Leadership - Perthera
Stock and Other Ownership Interests - Perthera
Patents, Royalties, Other Intellectual Property - Named as an inventor on patents filed by Perthera, Inc. (as an employee)
 
Adam Mueller
Research Funding - ViewRay (Inst)
 
Dzung Thach
Employment - Perthera
Stock and Other Ownership Interests - Perthera
 
Patricia Miren de Arbeloa
Employment - Perthera
 
Lynn McCormick Matrisian
Other Relationship - Abbvie (Inst); Amgen Foundation (Inst); AstraZeneca (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); CISCRP (Inst); Corcept Therapeutics (Inst); Cornerstone Pharmaceuticals (Inst); Covance (Inst); Elevation Oncology (Inst); FibroGen (Inst); Galera Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); LabCorp (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Myriad Genetics (Inst); Nestle health science (Inst); Novartis (Inst); Novocure (Inst); PhRMA Foundation (Inst); RenovoRx (Inst); SERVIER (Inst); Tempus (Inst); TYME (Inst); ViewRay (Inst)
 
Emanuel Petricoin
Leadership - Ceres Nanosciences; Perthera
Stock and Other Ownership Interests - Ceres Nanosciences; Perthera; Theralink
Consulting or Advisory Role - Ceres Nanosciences; Perthera; Theralink
Research Funding - Ceres Nanosciences (Inst); Deciphera; G1 Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst); SpringWorks Therapeutics
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Seagen; TriSalus Life Sciences
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma; RenovoRx
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Faraday Pharmaceuticals; Ipsen; Merus; Novartis; Pancreatic Cancer Action Network; Perthera; Valar Labs; Varian Medical Systems
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen
 
Atrayee Basu Mallick
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); BMS (I); Pfizer (I)
Consulting or Advisory Role - Bayer; deciphera; deciphera; Novartis
Research Funding - Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Prelude Therapeutics (Inst); Prelude Therapeutics (Inst); PTC therapeutics (Inst); Pyramid Biosciences (Inst); Rgenix (Inst); The Academic GI Cancer Consortium (Inst); TRACON Pharma (Inst)
 
Harish Lavu
No Relationships to Disclose
 
Charles J. Yeo
No Relationships to Disclose
 
Babar Bashir
Consulting or Advisory Role - Merck/Eisai
Research Funding - Amgen (Inst); Artios (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Elucida Oncology (Inst); Gritstone Bio (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); KAHR Medical (Inst); Lyell Immunopharma (Inst); Merck (Inst); Pionyr (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)
 
Avinoam Nevler
Stock and Other Ownership Interests - Envizion medical (TLV: ENVM)
Patents, Royalties, Other Intellectual Property - Patent pending for a class of mitochondrial inhibitors (Inst)